Resources

Poolbeg Pharma announces that the Korean Intellectual Property Office has notified the Company of its official decision to grant Poolbeg's Republic of Korea Immunomodulator II patent application providing protection to POLB 001 for the treatment of severe influenza to December 2038.  

The UKHSA Conference 2025, delivered in partnership with the FPH, will explore the full breadth of UKHSA’s work; from science-driven research to effective policy implementation.

Pioneer Group, the life science infrastructure and venture building specialist, has joined forces with Innovate UK, The Medical Research Council (MRC) and AstraZeneca, to deliver the AI in Health Accelerator 2024/2025 Programme.

Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials.

Pioneer Group has partnered Thermo Fisher Scientific to support biotech founders on their journey towards commercialising intellectual property in the healthcare and sustainability sectors.

Therakind announces that the United States Patent and Trademark Office has granted a patent protecting the Company’s novel multi-dose, needle-free version of its dry powder nasal drug delivery system, DriDose®.

Further strengthens Poolbeg's robust intellectual property portfolio

In two Newscasts time, we will know the outcome of the UK General Election to be held on Thursday, 4 July. Join our webinar tomorrow at 1 pm where we will discuss what we have learned from the campaigns and manifestoes about potential future policies and people important for our sector after the result.

A new spin-out company is set to transform the agricultural sector by revolutionising plant and animal breeding, as well as the development of inputs such as agrochemicals, biostimulants, biologicals, and plant nutrients.

Why to channel Scottish polymath Mary Somerville, how timing can make or break a startup, and other lessons from experts at All You Can Innovate 2024.

Notice of Allowance for Immunomodulator II further strengthens robust intellectual property portfolio

This Thursday marks Rare Disease Day, and as it is a leap year it is taking place on the rarest day of all – 29 February. There are 3.5 million people in the UK living with a rare condition and one in 17 people will be affected by a rare condition at some point in their lives.

I'm looking forward to the BIA Committee Summit this week. It will be great to see 200 members in Westminster at one of the most lively and insightful events we do each year. I know it's the volunteer expert army that gives the BIA its unique impact with government and it's always great to understand the committee's priorities and the ideas at the intersection between committees that arise from the event.

The BIA’s Intellectual Property Advisory Committee (IPAC) helps BIA understand and shape the environment for IP ownership to ensure strong protection for BIA member companies. Our EU policy subcommittee has taken a look at what a recent European decision means for the right to claim priority to an earlier filed patent application. This blog sets out some of the details of the case, and the practical implications for BIA members.​​​​​​​